(Q35580478)

9 August 2017

1 reference

title

Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis (English)

1 reference

9 August 2017

0 references

Pseudomonas aeruginosa

1 reference

Susan M Cheer

1

1 reference

9 August 2017

John Waugh

series ordinal

2

1 reference

9 August 2017

Stuart Noble

series ordinal

3

1 reference

9 August 2017

1 January 2003

1 reference

9 August 2017

1 reference

9 August 2017

63

1 reference

9 August 2017

22

1 reference

9 August 2017

2501-2520

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200363220-00015

9 August 2017

0 references

cites work

Inhalation of antibiotics in cystic fibrosis.

1 reference

12 December 2020

Tobramycin Serum Concentrations After Aerosol and Oral Administration in Cystic Fibrosis

1 reference

12 December 2020

Economic evaluation of Tobramycin nebuliser solution in cystic fibrosis

1 reference

12 December 2020

Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis

1 reference

12 December 2020

New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis

1 reference

12 December 2020

The effect of sublethal levels of antibiotics on the pathogenicity of Pseudomonas aeruginosa for tracheal tissue

1 reference

12 December 2020

A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group.

1 reference

12 December 2020

Inhaled antimicrobial therapy: from cystic fibrosis to the flu.

1 reference

12 December 2020

Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.

1 reference

12 December 2020

1 reference

12 December 2020

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

1 reference

12 December 2020

Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis

1 reference

12 December 2020

Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis

1 reference

12 December 2020

Rational treatment of pulmonary infections in patients with cystic fibrosis

1 reference

12 December 2020

Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.

1 reference

12 December 2020

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis

1 reference

12 December 2020

Long-term tobramycin aerosol therapy in cystic fibrosis

1 reference

12 December 2020

A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis

1 reference

12 December 2020

Protection by antibiotics against myeloperoxidase-dependent cytotoxicity to lung epithelial cells in vitro

1 reference

12 December 2020

New and emerging therapies for pulmonary complications of cystic fibrosis

1 reference

12 December 2020

TOBI: reducing the impact of pseudomonal infection.

1 reference

12 December 2020

Comparison of inhibitory and bactericidal activity of antipseudomonal antibiotics against Pseudomonas aeruginosa isolates from cystic fibrosis patients.

1 reference

12 December 2020

In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany

1 reference

12 December 2020

Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis

1 reference

12 December 2020

Inhaled antibiotics in cystic fibrosis: is there a therapeutic effect?

1 reference

12 December 2020

Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection

1 reference

12 December 2020

Inhibition of Pseudomonas aeruginosa exoenzyme expression by subinhibitory antibiotic concentrations

1 reference

12 December 2020

Nebulized antibiotics in cystic fibrosis

1 reference

12 December 2020

Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia

1 reference

12 December 2020

Aminoglycoside resistance: a worldwide perspective.

1 reference

12 December 2020

Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis

1 reference

12 December 2020

Administration of aerosolized antibiotics in cystic fibrosis patients

1 reference

12 December 2020

Assessment of potential ototoxicity following high-dose nebulized tobramycin in patients with cystic fibrosis

1 reference

12 December 2020

Nebulizer delivery of tobramycin to the lower respiratory tract

1 reference

12 December 2020

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

12 December 2020

Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis

1 reference

12 December 2020

Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis

1 reference

12 December 2020

Management of pulmonary disease in patients with cystic fibrosis

1 reference

12 December 2020

Resistance surveillance programs and the incidence of gram-negative bacillary resistance to amikacin from 1967 to 1985.

1 reference

12 December 2020

Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis

1 reference

12 December 2020

In-vitro effects of antimicrobial agents on Pseudomonas aeruginosa biofilm formation

1 reference

12 December 2020

Antimicrobial treatment of pulmonary colonization and infection by pseudomonas aeruginosa in cystic fibrosis patients

1 reference

12 December 2020

Decisions facing the cystic fibrosis clinician at first isolation of Pseudomonas aeruginosa

1 reference

12 December 2020

Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis

1 reference

12 December 2020

Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis.

1 reference

12 December 2020

Efficacy and safety of aerosolized tobramycin in cystic fibrosis

1 reference

12 December 2020

Pseudomonas aeruginosa and cystic fibrosis: Antibiotic therapy and the science behind the magic

1 reference

12 December 2020

Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis

1 reference

12 December 2020

10.2165/00003495-200363220-00015

Identifiers

DOI

1 reference

Dimensions Publication ID

9 August 2017

0 references

1 reference